# US 8,999,967 B2 · Tricyclic fused ring inhibitors of hepatitis C

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,999,967 B2
- Document ID: US8999967B2
- Status: Granted
- Kind: B2
- Application number: 13/877,151
- Filed: 2011-09-28
- Published: 2013-11-07
- Granted: 2015-04-07
- Earliest claimed: 2010-09-29
- Assignees: Presidio Pharmaceuticals, Inc.
- Applicants: Leping Li; Min Zhong
- Inventors: Leping Li; Min Zhong
- Web page: https://patentgrep.com/patent/US8999967B2

## CPC

- C07D 413/14: containing three or more hetero rings
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- C07D 401/14: containing three or more hetero rings
- C07D 403/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C07D 409/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are compounds, pharmaceutical compositions and combination therapies for treatment of hepatitis C.

## Claims

### Claim 1

A compound having a formula selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1.

### Claim 3

A compound having a formula selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 3)

A pharmaceutical composition comprising the compound of claim 3.